TQC 2938
Alternative Names: TQC-2938Latest Information Update: 18 Feb 2026
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 1 receptor-like 1 protein antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma
Most Recent Events
- 28 Nov 2025 Chia Tai Tianqing Pharmaceutical Group completes enrolment in the phase II trial for Allergic-rhinitis in China (NCT07052097)
- 04 Jul 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Allergy in China (Parenteral, Injection) (NCT07052097)
- 17 May 2025 Adverse events and pharmacokinetic data from a phase I trial in healthy volunteers presented at the 121st International Conference of the American Thoracic Society (ATS-2025)